Instituto Butantan is second to none in the Southern Hemisphere when it comes to flu vaccine manufacturing capacity. We expect to achieve the WHO prequalification by 2020. Besides, we are presently developing:
Butantan has already built its dengue vaccine facility, designed to produce 30 million annual doses (nominal capacity). The institute has developed its proprietary process based on a tetravalent, recombinant vaccine candidate created by the National Institutes of Health. In 2019, Butantan will conclude the clinical trials for this candidate.
The Butantan’s future mAbs manufacturing plant is currently under construction. Butantan-Libbs Farmacêutica partnership involves a technology transfer for the manufacturing of six monoclonal antibodies used in the treatment of various types of cancer.
Future manufacturing of the mAbs at Instituto Butantan will provide Brazilian public health with drugs similar to Trastuzumab, Rituximab, Bevacizumab, Etanercept and Palivizumab.